|
1.
|
|
10 p, 1.7 MB |
Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis
/
Papp, Kim A (K Papp Clinical Research) ;
Thoning, Henrik (LEO Pharma) ;
Gerdes, Sascha (Center for Inflammatory Skin Diseases. Dept. of Dermatology. Venereology and Allergology. University Medical Center Schleswig-Holstein) ;
Megna, Matteo (Section of Dermatology. Dept. of Clinical Medicine and Surgery. University of Naples Federico II) ;
Brandi, Henrik (LEO Pharma) ;
Jablonski Bernasconi, Marie Y. (LEO Pharma) ;
Yélamos, Oriol (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Background and objectives: Once-daily, fixed-combination calcipotriol 50 μg/g (Cal) plus betamethasone dipropionate 0. 5 mg/g (BD) is available in aerosol foam and cream formulations. As no head-to-head data are available, we use a matching-adjusted indirect comparison (MAIC) approach to compare Cal/BD foam and cream. [...]
2022 -  10.1080/09546634.2022.2095330
Journal of Dermatological Treatment, Vol. 33 Núm. 7 (2022) , p. 3005-3013
|
|
|
2.
|
|
11 p, 1.5 MB |
Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis : interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up
/
Papp, Kim A (K Papp Clinical Research and Probity Medical Research) ;
Lebwohl, M. G. (Icahn School of Medicine at Mount Sinai) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Ohtsuki, M. (Jichi Medical University) ;
Beissert, Stefan (Department of Dermatology. University Hospital Carl Gustav Carus. TU Dresden) ;
Zeng, J. (AbbVie Inc.) ;
Rubant, S. (AbbVie Inc.) ;
Sinvhal, R. (AbbVie Inc.) ;
Zhao, Y. (AbbVie Inc.) ;
Soliman, A.M. (AbbVie Inc.) ;
Alperovich, G. (AbbVie Inc.) ;
Leonardi, C. (Central Dermatology. Richmond Heights)
Background: Psoriasis is a chronic inflammatory skin disease requiring prolonged treatment. New biologic therapies require long-term evaluation to assess the durability of their efficacy and safety profiles over time. [...]
2021 - 10.1111/bjd.20595
British journal of dermatology, Vol. 185 Núm. 6 (december 2021) , p. 1135-1145
|
|
|
3.
|
|
16 p, 1.2 MB |
Deucravacitinib in Moderate to Severe Psoriasis : Clinical and Quality-of-Life Outcomes in a Phase 2 Trial
/
Thaçi, Diamant (University of Luebeck) ;
Strober, Bruce (Yale University) ;
Gordon, Kenneth B. (Medical College of Wisconsin) ;
Foley, Peter (The University of Melbourne) ;
Gooderham, Melinda (Queen's University and Probity Medical Research) ;
Morita, Akimichi (Nagoya City University) ;
Papp, Kim A. (Clinical Research and Probity Medical Research) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Menter, M. Alan (Baylor University Medical Center) ;
Colombo, Matthew J. (Bristol Myers Squibb) ;
Elbez, Yedid (Bristol Myers Squibb) ;
Kisa, Renata M. (Bristol Myers Squibb) ;
Ye, June (Bristol Myers Squibb) ;
Napoli, Andrew A. (Bristol Myers Squibb) ;
Wei, Lan (Bristol Myers Squibb) ;
Banerjee, Subhashis (Bristol Myers Squibb) ;
Merola, Joseph F. (Harvard Medical School) ;
Gottlieb, Alice B. (Icahn School of Medicine at Mount Sinai) ;
Universitat Autònoma de Barcelona
Deucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that demonstrated therapeutic benefit in a Phase 2 clinical trial of adults with moderate to severe plaque psoriasis. This analysis was designed to evaluate the effect of deucravacitinib on additional clinical and quality-of-life (QoL) outcomes and assess the relationship between these outcomes in adults with psoriasis. [...]
2022 - 10.1007/s13555-021-00649-y
Dermatology and Therapy, Vol. 12 (january 2022) , p. 495-510
|
|
|
4.
|
|
14 p, 980.7 KB |
Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis : A Machine Learning Predictive Model
/
Papp, Kim A. (K Papp Clinical Research and Probity Medical Research) ;
Soliman, Ahmed M. (AbbVie, Inc) ;
Done, Nicolae (Analysis Group, Inc) ;
Carley, Christopher (Analysis Group, Inc) ;
Lemus Wirtz, Esteban (Analysis Group, Inc) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Risankizumab has demonstrated efficacy in treating moderate-to-severe psoriasis. The phase-3 IMMhance trial (NCT02672852) examined the effect of continuing versus withdrawing from risankizumab treatment on psoriasis severity, including the Psoriasis Area and Severity Index (PASI) and static Physician Global Assessment (sPGA). [...]
2021 - 10.1007/s13555-021-00550-8
Dermatology and Therapy, Vol. 11 (may 2021) , p. 1291-1304
|
|
|
5.
|
|
18 p, 504.6 KB |
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis : Results from Greater Than 17,000 Patient-Years of Exposure
/
Armstrong, April W (Keck School of Medicine of the University of Southern California. Department of Clinical Research) ;
Paul, Carle (Paul Sabatier University. Dermatology Department, Toulouse University Hospital (CHU)) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Boehncke, Wolf-Henning (University of Geneva. Department of Pathology and Immunology) ;
Freeman, Michael (The Skin Centre, Benowa, QLD Australia) ;
Torii, Hideshi (Tokyo Yamate Medical Center. Division of Dermatology) ;
Papp, Kim (K Papp Clinical Research and Probity Medical Research) ;
Griffiths, Christopher E. M. (NIHR Manchester Biomedical Research Centre. Dermatology Centre, Salford Royal Hospital, University of Manchester) ;
Blauvelt, Andrew (Oregon Medical Research Center) ;
Reich, Kristian (Skinflammation® Center, Hamburg, Germany) ;
Gooderham, Melinda (Centre for Dermatology and Probity Medical Research, Peterborough, ON Canada) ;
Terui, Tadashi (Nihon University School of Medicine. Department of Dermatology) ;
Renda, Lisa (Eli Lilly and Company) ;
Agada, Noah (Eli Lilly and Company) ;
Xu, Wen (Eli Lilly and Company) ;
Gallo, Gaia (Eli Lilly and Company) ;
Lebwohl, Mark G. (Icahn School of Medicine at Mount Sinai. Department of Dermatology) ;
Universitat Autònoma de Barcelona
Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis. We examined the safety and tolerability of up to 5 years of ixekizumab therapy in patients with psoriasis. [...]
2019 - 10.1007/s13555-019-00340-3
Dermatology and Therapy, Vol. 10 (november 2019) , p. 133-150
|
|
|
6.
|
|
9 p, 310.0 KB |
Long-term safety and tolerability of apremilast in patients with psoriasis : Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)
/
Crowley, Jeffrey (Bakersfield Dermatology) ;
Thaçi, Diamant (Universitätsklinikum Schleswig-Holstein (Alemanya)) ;
Joly, Pascal (Department of Dermatology, Hôpital Charles Nicolle, Université de Rouen) ;
Peris, Ketty (Universitá Cattolica del Sacro Cuore, Roma) ;
Papp, Kim A. (Probity Medical Research, Waterloo) ;
Gonçalves, Joana (Celgene Corporation) ;
Day, Robert M. (Celgene Corporation) ;
Chen, Rongdean (Celgene Corporation) ;
Shah, Kamal (Celgene Corporation) ;
Ferrándiz, Carlos (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Cather, Jennifer C. (Modern Research Associates, Dallas) ;
Universitat Autònoma de Barcelona
2017 - 10.1016/j.jaad.2017.01.052
Journal of the American Academy of Dermatology, Vol. 77 Núm. 2 (2017) , p. 310
|
|
|
7.
|
|
1 p, 320.3 KB |
Correction to : Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
/
Blauvelt, Andrew (SW Locust St., Suite G, Portland, OR 97223 USA) ;
Papp, Kim A. (Waterloo, Canada) ;
Griffiths, Christopher E. M. (Manchester, UK) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Weisman, Jamie (Medical Dermatology Specialists, Inc., Atlanta, GA USA) ;
Dutronc, Yves (Indianapolis, IN USA) ;
Kerr, Lisa Farmer (Indianapolis, IN USA) ;
Ilo, Dapo (Indianapolis, IN USA) ;
Mallbris, Lotus (Indianapolis, IN USA) ;
Augustin, Matthias (University Medical Center Hamburg-Eppendorf) ;
Universitat Autònoma de Barcelona
2018 - 10.1007/s40257-018-0353-x
American Journal of Clinical Dermatology, Vol. 19 (march 2018) , p. 457
|
|
|
8.
|
|
8 p, 420.3 KB |
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders : a Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
/
Blauvelt, Andrew (SW Locust St., Suite G, Portland, USA) ;
Papp, Kim A. (Waterloo, Canada) ;
Griffiths, Christopher E. M. (Manchester, UK) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Weisman, Jamie (Medical Dermatology Specialists, Inc., Atlanta, GA USA) ;
Dutronc, Yves (Indianapolis, IN USA) ;
Kerr, Lisa Farmer (Indianapolis, IN USA) ;
Ilo, Dapo (Indianapolis, IN USA) ;
Mallbris, Lotus (Indianapolis, IN USA) ;
Augustin, Matthias (University Medical Center Hamburg-Eppendorf) ;
Universitat Autònoma de Barcelona
Patients with psoriasis who have an inadequate response to one biologic may benefit from switching to a new biologic, such as ixekizumab, a high affinity monoclonal antibody that selectively targets interleukin (IL)-17A. [...]
2017 - 10.1007/s40257-016-0246-9
American Journal of Clinical Dermatology, Vol. 18 (january 2017) , p. 273-280
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
